Origin and Pharmacokinetics
Historically, antitumor antibiotics are metabolic products of soil-dwelling Streptomyces species. Chemically, doxorubicin is a hydroxylated analog of another anthracycline, daunorubicin.
The drug is completely degraded by gastrointestinal enzymes and must therefore be administered exclusively via intravenous infusion. In its standard formulation, it does not cross the blood-brain barrier (BBB), though modern pharmacology utilizes nanotechnology-based formulations (nanoparticles) of doxorubicin to overcome this limitation.
In the body, the drug undergoes biotransformation, including glutathione conjugation. Elimination occurs primarily via biliary excretion into the feces, with a smaller fraction excreted in the urine.
Mechanism of Action
The drug exerts its cytotoxic effects through four main mechanisms:
- Topoisomerase II Inhibition: This is the primary mechanism of action, which disrupts the spatial conformation and replication of DNA.
- Intercalation: Due to its specific chemical structure and molecular size, the drug inserts itself between adjacent DNA base pairs. This blocks nucleic acid synthesis (DNA and RNA) and induces DNA strand breaks.
- Oxidative Stress: The drug stimulates the production of free radicals and peroxides, leading to direct oxidative damage and DNA strand breakage.
- Membrane Toxicity: By binding to the cell membrane, the antibiotic disrupts its transport functions, causing intracellular water and electrolyte imbalance.
Indications
Unlike daunorubicin, which has a narrow spectrum, doxorubicin exhibits a broad spectrum of antitumor activity. It is indicated for:
- Solid Tumors: Sarcomas, breast carcinomas, and lung carcinomas.
- Hematologic Malignancies: Lymphomas, acute leukemias.
The drug is frequently used in combination chemotherapy regimens. For example, along with the monoclonal antibody rituximab, cyclophosphamide, vincristine, and prednisone, it is used in the treatment of various lymphomas and leukemia protocols.
Side Effects and Toxicity
Like most cytotoxic agents, the drug has significant adverse effects:
- Hematologic Toxicity: This is the dose-limiting factor. It manifests as myelosuppression—primarily neutropenia, and less commonly thrombocytopenia.
- Cardiotoxicity: The most severe complication and a classic example of specific organ toxicity. The pathogenesis involves free radical generation and lipid peroxidation in cardiomyocytes.
- Prevention: Dexrazoxane is used (chelating iron and copper ions to reduce radical production), or liposomal formulations of the drug (such as Caelyx) are employed to minimize myocardial damage.
- Local Reactions: Extravasation (accidental leakage into surrounding tissues) leads to severe tissue necrosis.
- Specific Characteristics: The drug itself has a deep red color, which can cause the patient's urine and visible superficial veins to turn a striking reddish-brown color.
Formulation and Administration
The drug is supplied in vials as a lyophilized powder (e.g., 1 mg/vial). Dosing is strictly individualized based on the patient's body surface area: administered intravenously at 60–75 mg/m².
Prescription example:
Rp.: Doxorubicini 0.001 D.t.d. N. 10 in flac. S. Reconstitute vial contents in normal saline, administer intravenously per protocol.